Please login to the form below

Yescarta

This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Sales of its Kite-partnered CAR-T cell therapy Yescarta (axicabtagene ciloleucel) climbed to $156m in the quarter, an increase on the $120m it generated for the same period in 2019.

Latest news

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) which are approved for haematologic cancers, TCRs has the potential to
FDA begins speedy review of BMS’ CAR-T liso-cel

If it does receive approval, liso-cel will come onto the market after rival Novartis’ Kymriah (tisangenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel). ... BMS alleged that Kite scientists copied research from the scientists at
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene ciloleucel) is available for the treatment of diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma.
EMA begins review of Kite’s CAR-T for mantle cell lymphoma

Gilead/Kite already have one approved CAR-T therapy in the arsenal – Yescarta (axicabtagene ciloleucel) – which is approved for diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma. ... The first CAR-T therapy to be approved
EU grants conditional approval to Roche's lymphoma drug Polivy

Gilead Sciences’ Yescarta and Novartis’ Kymriah, to be ready for use.

More from news
Approximately 12 fully matching, plus 51 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

as Kymriah and Yescarta.
25 Women Leaders in UK Healthcare (part 2)

It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
Bluebird: on a mission to ‘recode’ the DNA of healthcare

years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”

can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
Cell and gene therapy

Cell and gene therapies are currently expensive to manufacture. We do not believe that recently marketed products, with US prices ranging from $373, 000 for Yescarta to $850, 000 for Luxturna,

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

Training the next generation of biotech leaders

In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...